admin – Lophos Pharmaceuticals

Lophos Announces Listing on the Canadian Securities Exchange

by admin in Press Releases August 31, 2023

Vancouver, British Columbia, August 31, 2023 – Lophos Holdings Inc. (“Lophos“, or the “Company“) is pleased to announce that its common shares have been approved for listing on the Canadian Securities Exchange (the “CSE“) and the Company expects to commence trading on the CSE on or around September 06, 2023, under the ticker symbol “MESC“. […]

Lophos Pharma: Exploring the Potential of Mescaline

by admin in Press Releases February 24, 2022

Lophos Pharma is a Canadian peyote-focused psychedelics company. It was co-founded by wife and husband duo Claire and Evan Stawnyczy to explore mescaline’s potential in a range of indications, optimize the cultivation of peyote, and preserve the plant. It’s an ambitious plan in an emerging sector that has so far embraced the possibilities of compounds such […]

Lophos Pharmaceuticals Submits Application for Controlled Drugs and Substances Dealer’s License

by admin in Press Releases February 17, 2022

TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE) — Lophos Holdings (The “Company”) is pleased to provide an update on its wholly owned subsidiary Lophos Pharmaceuticals (“Lophos”). Lophos is a psychedelic research company primarily focused on novel therapeutic treatments derived from Peyote (Lophophora williamsii). Lophos has made significant strides in launching operations at their recently acquired 10,000 square foot […]

G2 Acquires Lophos Pharma, a peyote focused psychedelics company

by admin in Press Releases January 21, 2022

TORONTO, Jan. 21, 2022 (GLOBE NEWSWIRE) — Greenridez 2.0 Acquisitions Corp. (the “Company“) is pleased to announce that it has completed its acquisition of psychedelic research company Lophos Pharma (“Lophos”). Lophos Pharma is a psychedelic research company primarily focused on novel therapeutic treatments derived from Peyote (Lophophora williamsii). The Company strongly supports Lophos Pharma’s belief in Peyote’s […]

All posts by: admin

Lophos Announces Listing on the Canadian Securities Exchange

Lophos Pharma: Exploring the Potential of Mescaline

Lophos Pharmaceuticals Submits Application for Controlled Drugs and Substances Dealer’s License

G2 Acquires Lophos Pharma, a peyote focused psychedelics company

EMAIL (GENERAL INQUIRY)

EMAIL (INVESTOR INQUIRY)